| Form of release | Blister (25 tablets), Pack (100 tablets) |
|---|---|
| International Name | Ostarine (MK-2866) |
| Chemical Name | (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide |
| Type of Drug Combination | SARM (selective androgen receptor modulator) |
| Molecular Formula | C19H14F3N3O3 |
| Molecular Weight | 389.33 g/mol |
| Halflife | 22–24 hours, 22–24 hours |
| Mechanism of Action | Selectively binds to androgen receptors in muscle and bone tissue, activating anabolic processes without significantly affecting the prostate or other androgen-dependent organs. |
| Anabolic Activity | Average |
| Androgenic Activity | Very low |
| Main Effects | Increase in lean muscle mass, improved tone and endurance, muscle preservation during calorie deficit, accelerated recovery |
| Side Effects | Mild suppression of testosterone with prolonged use, fatigue and mild mood swings are possible |
| thenecessityofpct | Recommended for long-term courses (>6 weeks), Recommended for long-term courses (>6 weeks) |
| Recommended Dosage | 10–30 mg per day |
| Course Duration | 6–10 weeks |
| Reception Hours | Once a day (at any time, preferably at the same time) |
| Impact on Estrogens | No |
| Impact on the Liver | No |
| Storage | In a dry, cool place, protected from light, at a temperature not exceeding 25°C, In a dry, cool place, protected from light, at a temperature not exceeding 25°C |
| Use by Women | Acceptable in small doses (5–10 mg per day) without significant risk of virilization |
| Detection Period in the body | Up to 3–4 weeks |
